Article Text

PDF
CD24 shows early upregulation and nuclear expression but is not a prognostic marker in colorectal cancer
  1. M A H Ahmed1,2,
  2. A Al-Attar3,
  3. J Kim4,
  4. N F S Watson5,
  5. J H Scholefield5,
  6. L G Durrant3,
  7. M Ilyas1
  1. 1
    Division of Pathology, School of Molecular Medical Sciences, Queen’s Medical Centre Campus, University of Nottingham, Nottingham, UK
  2. 2
    Department of Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
  3. 3
    Academic Department of Clinical Oncology, School of Molecular Medical Sciences, City Hospital Campus, University of Nottingham, Nottingham, UK
  4. 4
    Department of Hospital Pathology, The Catholic University of Korea, Seoul, Korea
  5. 5
    Department of Gastrointestinal Surgery, Queen’s Medical Centre Campus, University of Nottingham, Nottingham, UK
  1. Correspondence to Professor M Ilyas, School of Molecular Medical Sciences, Division of Pathology, Queen’s Medical Centre, Nottingham NG7 2UH, UK; mohammad.ilyas{at}nottingham.ac.uk

Abstract

Background and aims: The putative stem cell marker CD24 is a small, heavily glycosylated, cell surface molecule which was originally associated with tumour metastasis. Recently it has been reported to be upregulated and of prognostic importance in colorectal tumours. The study aims to study the prognostic value of CD24 in a large series of colorectal cancer (CRC).

Methods: CD24 protein expression was examined by immunohistochemistry. A total of 10 whole tissue sections (WTS) of adenoma and 345 CRCs arranged as tissue microarrays (TMAs) were evaluated. For comparison with non-neoplastic tissue, 10 WTS containing tumour with associated non-neoplastic tissue were also studied.

Results: None of the samples of normal tissue (adjacent to tumour) showed CD24 expression. In the tumours, CD24 expression was seen on the luminal surface of the cells, within the cytoplasm and, unexpectedly, also within the nucleus. Positive immunostaining was seen in 9/10 (90%) adenomas and 313/345 (91%) of CRCs. Weak statistical associations were found between CD24 expression and some clinicopathological features. In contrast to other published studies, however, the analysis did not show any association between CD24 expression and poor prognosis—if anything it was found that loss of CD24 expression appeared to be more related to poor outcome.

Conclusion: Upregulation of CD24 is an early and common event during the development of CRC and it may be expressed in any cellular compartment, including the nucleus. CD24 is not, however, a good prognostic marker in CRC.

Statistics from Altmetric.com

Footnotes

  • Funding This work was funded by the University of Nottingham.

  • Competing interests None.

  • Ethics approval Ethics approval was provided by the Local Research Ethics Committee and the Trust Research and Development office.

  • Provenance and peer review not commissioned; externally peer reviewed

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.